Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on July 30, 2008, covering events occurring on July 24, 2008, and July 29, 2008. The filing details the company's ongoing private placement of equity securities.
Key Financial Metrics and Capital Raise
- Total Proceeds Reported: $1,099,088.88 raised across two closings ($949,000 on July 24 and $150,088.88 on July 29).
- Shares Issued: 808,082 shares of restricted common stock sold at $1.36 per share.
- Warrants Issued: Investors received warrants to purchase 50% of the shares purchased (404,041 warrants) at an exercise price of $3.00 per share, exercisable for five years.
- Placement Agent Fees: New Castle Financial Services LLC received 10% of gross proceeds raised ($100,000 total in cash fees) plus a warrant for 10% of the shares placed (336,390 shares).
- Overall Placement Status: The company has issued an aggregate of 3,436,700 shares and 1,718,350 warrants toward a total offering size of up to 4,411,764 shares and 2,205,882 warrants.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the increase in outstanding equity and potential dilution resulting from the sale of restricted stock and the issuance of warrants to 13 total investors (11 on July 24 and 2 on July 29). The filing incorporates the terms of the definitive agreement regarding the private placement.
Outlook, Risks, and Unusual Items
- Warrant Terms: Warrants are immediately exercisable. ChromaDex retains the right to repurchase warrants at $4.50 per share or cancel them at $1.50 per share.
- Regulatory Status: Securities were sold under Section 4(2) of the Securities Act of 1933 and Regulation D exemptions, meaning they are restricted securities.
- Management Commentary: The filing contains no forward-looking guidance or management commentary beyond the mechanics of the capital raise.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the cash balance impact of the $1.099 million raise versus the $100,000 in placement fees paid.
- Review the remaining capacity of the private placement (approx. 975,682 shares remaining).
- Check the company's current cash runway given the lack of revenue data in this specific filing.